Gilead Sciences said on Thursday it would donate about 5,000 vials of its antiviral drug remdesivir to the Rwanda Medical ...
The stock's fall snapped a five-day winning streak.
12h
Gilead Sciences Inc (GILD) reports robust financial performance with significant sales growth in key therapeutic areas and ...
Gilead Merger AstraZeneca, the UK’s largest drugmaker valued at $140bn, has reportedly contacted Gilead Sciences, an American ...
Fintel on MSN2d
Wells Fargo Upgrades Gilead Sciences (GILD)Fintel reports that on October 7, 2024, Wells Fargo upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Accolade (ACCD – Research Report) and Gilead ...
On Tuesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $85.21 which represents a slight increase of $0.78 or 0.92% from the prior close of $84.43. The stock opened at ...
11h
Future Financial Wealth Managment LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in ...
Analyst Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report) and keeping the price target at ...
Gilead Sciences Inc. closed $3.44 short of its 52-week high ($87.87), which the company achieved on January 19th.
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $77.91, along ...
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback